Vinod Kumar Rustgi MD MBA

Biliary Tract Disease, Hepatology & Liver Transplantation, Clinical Informatics

Distinguished Professor of Medicine (Gastroenterology)/Director of Hepatology. Professor of Epidemiology Professor of Pathology & Lab Medicine Rutgers Robert Wood Johnson Medical School

Join to view full profile

125 Paterson StSte 5100New Brunswick, NJ 08901
Phone+1 732-235-7784
Fax+1 732-235-7792

Dr. Rustgi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rustgi's full profile Already have an account?

Summary

Dr. Vinod Rustgi is a gastroenterologist based in New Brunswick, NJ, specializing in biliary tract disease, hepatology, and liver transplantation, with a focus on clinical informatics. He received his medical education from Johns Hopkins University School of Medicine and completed fellowships in gastroenterology and liver diseases at Stanford and the National Institutes of Health. He is experienced in conditions such as gastroesophageal reflux, hepatology, viral hepatitides, hepatic cirrhosis, and transplant hepatology. Dr. Rustgi has contributed to multiple clinical trials related to hepatitis C and has several publications focusing on liver diseases. His career includes significant roles such as a staff position at Inova Fairfax Medical Campus and a Clinical Professorship at Georgetown University. Among his honors are fellowships from the American Association for the Study of Liver Diseases and the Royal College of Physicians, as well as a Distinguished Professorship from Rutgers Robert Wood Johnson Medical School.

Education & Training

Johns Hopkins UniversityM.B.A, 2005 - 2009
Clinical Center at the National Institutes of HealthFellowship, Liver Diseases, 1985 - 1987
Stanford Health Care-Sponsored Stanford UniversityFellowship, Gastroenterology, 1982 - 1985
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1980 - 1982
Johns Hopkins University School of MedicineClass of 1979

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - 2028
VA State Medical License 1981 - 2028
NJ State Medical License 2016 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

Fellow American College of Gastroenterology, 2023-2025
Fellowship Royal College of Physicians (UK), 2023-2025
Distinguished Professorship Rutgers Robert Wood Johnson Medical School, 2023-2025

Clinical Trials

YM443 in Subjects With Functional Dyspepsia Start of enrollment: 2004 Mar 10
COMPLETED
PHASE2
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
TERMINATED
PHASE2
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
COMPLETED
PHASE2

Publications & Presentations

PubMed

Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population-Based Cohort Study.
Mohamed I Elsaid, Holli A Loomans-Kropp, Yesung Kweon, Vinod K Rustgi, Cecilia Dapino
Cancer Medicine. 2026-03-01
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.
Chu-Tian Wu, Giovanni Targher, Christopher D Byrne, Zobair M Younossi, Matthew J Armstrong
Gut. 2026-01-21
With Gratitude and Pride: Reflections From the Editors-in-Chief.
Vinod K Rustgi, Shanthi Srinivasan
Gastro Hep Advances. 2026-01-01

Journal Articles

New Perspectives and Advances in Risk-Factor Assessment, Diagnosis, and Treatment of Hepatitis C.
Rustgi VK, Practical Gastroenterology
Hepatitis C virus treatment related anemia is associated with higher sustained virologic response rate.
Sulkowski MS, Shiffman ML…Rustgi V…et al, Gastroenterology;139 (5): 1602-11, 1611.e1
Racial differences in hepatitis C treatment eligibility.
Melia MT…Rustgi VK…et al, Hepatology: 54(1): 70-8

Books/Book Chapters

Gastrointestinal and Hepatic Complications in Pregnancy.
Rustgi VK, Cooper JNEditors: Rustgi VK, Cooper JN.John Wiley & Sons, New York
Endoscopy in the pregnant patient.
Rustgi VK, Cooper JN, Colcher H
Cirrhosis and pregnancy.
Rustgi VK

Abstracts/Posters

The effect of rat gamma interferon on antipyrine metabolism by the isolated perfused rat liver.
Rustgi VK, Suou T, Jones DB, Lisker-Melman M, Vergalla J, Jones EA, Hoofnagle JH, AFCR National Meetings; Clinical Research, 35 (3): 414A, San Diego, CA
Liver Transplantation for the Alcoholic Patient.
Rustgi VK, Transplant Forum pp. 2-4
Chronic domiciliary respiratory support by portable positive pressure ventilators.
Tsou E, Waldhorn R, Rustgi VK, Am. Rev. Resp. Dis. 127: 125

Other

A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon based therapy for chronic hepatitis C infection.
Reddy KR, Rustgi VK, Zeuzem S, Gane E, Lim SG, Jia JD, Belanger B, George S, Harb G, annual European Association for the Study of the Liver Meeting
http://www.easl.ch/easl2006/program/SessionIndex.asp
Valopicitabine (NM283), alone or with peg-interferon, compared to peg Interferon/Ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to ...
Afdhal N, O’Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P… Rustgi VK… et al, annual European Association for the Study of the Liver Meeting
http://www.easl.ch/easl2006/program/SessionIndex.asp
Pre-dosing taribavirin prior to combination therapy with pegylated interferon alfa-2B versus standard combination dosing: 24-week interim results examining safety and ...
Palmer M, Rubin R, Rustgi VK, Li D & Murphy B, annual European Association for the Study of the Liver Meeting
http://www.easl.ch/liver-meeting/program/SessionIndex.asp

Press Mentions

Most Liver Cancer Preventable, Lancet Commission FindsAugust 6th, 2025
Study: Bariatric Surgery Reduces Risk of Heart DiseaseNovember 19th, 2022
Weight-Loss Surgery Slashes Odds for Heart Attack in Very Obese PeopleNovember 16th, 2022